OBJECTIVE: To evaluate risk factors in @entity1 with locally advanced @entity5 (LACC) undergoing pretherapeutic laparoscopic paraaortic lymphadenectomy (LPL), as well as the progression-free and overall survival rates specifically in the subgroup of @entity1 with metastatic paraaortic lymph nodes (PLN). DESIGN: Retrospective study conducted on demographic data, pathological and surgical findings, complications and disease-status, recorded for LACC @entity1 undergoing LPL during the period 2009-2015. DESIGN: classification. Retrospective study. SETTING: Department of Gynecologic Oncology of the Complejo Hospitalario Universitario Insular-Materno Infantil, @entity18848 Islands, Spain. @entity1 : @entity1 with LACC undergoing pretherapeutic LPL. All @entity1 were treated with definitive chemoradiotherapy after surgery and those with metastatic PLN received extended lumbo-aortic radiation therapy. INTERVENTIONS: Survival analysis was performed with the Kaplan-Meier method. Statistical significance was considered for p-values<0.05. MEASUREMENTS AND MAIN RESULTS: The study included 139 @entity1 . The median age was 48 years (28-73). The most frequent histological type was @entity957 (77%) and the most frequent 2009 FIGO stage was IIB (48.2%). LPL identified metastatic PLN in 18.7% of @entity1 (26). The mean OS for the whole population, after 23 months follow-up, was 68.2 months (CI95% 63-73.4). For @entity1 without paraaortic @entity3 , the mean survival time was 76.9 months (CI95% 70.3-80.4), while for @entity1 with positive PLN the median survival time was 21 months (CI95% 6.1-35.9) (p < 0.0001). A logistic regression analysis revealed that the presence of metastatic PLN and the @entity5 size (> 5 cm) were both independent risk factors for poor survival [(OR117.5; CI95% 11.6-990.2; p < 0.0001) and (OR21.5; CI95% 2-230.3; p = 0.01)]. CONCLUSION: LACC @entity1 with metastatic PLN had a poor prognosis and low survival rate. We postulate that this finding could be accounted for by the presence of @entity262 and high-recurrence rate following therapy. Efforts should be made to improve available therapeutic strategies for this particular subgroup of @entity1 .

Should the Presence of Metastatic Para-aortic Lymph Nodes in Locally Advanced XXXX Lead to More Aggressive Treatment Strategies?

@entity1 :: ('9606', 'Species') :: ['patients', 'Women', 'PATIENTS'] @entity18848 :: ('9135', 'Species') :: ['Canary'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cervical cancer'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous-cell carcinoma'] @entity262 :: ('MESH:D034721', 'Disease') :: ['hidden systemic disease'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']
@entity5 :: (MESH:D009369,Disease) :: ['Cervical Cancer']
